Headquartered in Hackensack, New Jersey, Amorcyte, Inc. is a biopharmaceutical company focusing on the development of cellar therapies to treat cardiovascular disease.

Our initial emphasis will be on acute myocardial infarct. Our lead product is a CD34+ enriched cellular product that has demonstrated significant activity in repairing myocardium after an AMI.

Amorcyte initiated the Phase I trial in January of 2006 at Emory University. The goal of the first phase of this study is to establish the dose potency, identity, efficacy, and safety of AMR-001.